L
1.41
0.00 (0.00%)
| Penutupan Terdahulu | 1.41 |
| Buka | 1.40 |
| Jumlah Dagangan | 236,033 |
| Purata Dagangan (3B) | 1,345,061 |
| Modal Pasaran | 184,849,248 |
| Harga / Jualan (P/S) | 26.26 |
| Harga / Buku (P/B) | 2.16 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 23 Mar 2026 |
| Margin Operasi (TTM) | -1,508.09% |
| EPS Cair (TTM) | -1.17 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -17.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 206.15% |
| Nisbah Semasa (MRQ) | 0.750 |
| Aliran Tunai Operasi (OCF TTM) | -43.99 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -28.50 M |
| Pulangan Atas Aset (ROA TTM) | -92.04% |
| Pulangan Atas Ekuiti (ROE TTM) | -1,897.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Menurun |
| Medical Devices (Global) | Bercampur | Menurun | |
| Stok | Lucid Diagnostics Inc. | Menaik | Menaik |
AISkor Stockmoo
0.4
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 2.5 |
| Purata | 0.38 |
|
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 34.54% |
| % Dimiliki oleh Institusi | 10.13% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities |
| 21 Jan 2026 | Pengumuman | Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard® |
| 30 Dec 2025 | Pengumuman | PAVmed Announces Reverse Stock Split |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |